- Home
- SILC vs GALT Comparison
SILC vs GALT Comparison
Compare SILC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | GALT |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 232.3M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SILC | GALT |
|---|---|---|
| Price | $14.85 | $6.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 14.0K | ★ 440.3K |
| Earning Date | 01-29-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,509,000.00 | N/A |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $14.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.44 | $0.73 |
| 52 Week High | $19.37 | $6.66 |
Technical Indicators
Market Signals| Indicator | SILC | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 57.01 |
| Support Level | $14.15 | $5.10 |
| Resistance Level | $14.88 | $6.32 |
| Average True Range (ATR) | 0.51 | 0.52 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 13.32 | 66.03 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.